Gilead Sciences (GILD) Announces Two Odefsey Phase 3b Studies Met Primary Objectives
July 21, 2016 4:33 PM
Gilead Sciences, Inc. (Nasdaq: GILD) announced that two Phase 3b switch studies evaluating Odefsey® (emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) for ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
